Expression of CD69 after in vitro stimulation: A rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 1, 1996, Pages 95-104

  Krowka, John F ^a   Cuevas, Bernardo ^a   Maron, David C ^a   Steimer, Kathelyn S ^b   Ascher, Michael S ^a   Sheppard, Haynes W ^a,c  

^a VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Activation; CD69; gp120; HIV

Indexed keywords

CD69 ANTIGEN;

ARTICLE; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030033528     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199601010-00013     Document Type: Article

References (45)

1. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital Cohort. Br Med J 1988;296:745-50.
2. Krowka JF, Stites DP, Mills J, et al. Effects of interleukin 2 and large envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus. Clin Exp Immunol 1988;72:179-88.
3. Gluckman JC, Klatzmann D, Cavaille-Coll M, et al. Is there correlation of T cell proliferative functions and surface marker phenotypes in patients with acquired immune deficiency syndrome or lymphadenopathy syndrome? Clin Exp Immunol 1985;60:8-16.
4. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, Shearer GM. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989;84:1892-9.
5. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-62.
6. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J AIDS 1991;4:704-12.
7. Osmond DH, Shiboski S, Bacchetti P, Winger EE, Moss AR. Immune activation markers and AIDS prognosis. AIDS 1991;5:505-11.
8. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4.
9. Sheppard HW, Ascher MS, The natural history and pathogenesis of HIV infection. Annu Rev Microbiol 1992;46:533-64.
10. Giorgi JV, Detels R, T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989;52:10-8.
11. Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J AIDS 1991;4:1227-32.
12. Kara T, Jung LK, Bjorndahl JM, Fu SM. Human T cell activation II. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 1986;164:1988-2005.
13. Lanier LL, Buck DW, Rhodes L, et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 1988;167:1572-85.
14. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989;143:1123-8.
15. Shalaby MR, Krowka JF, Gregory TJ, et al. The effects of HIV recombinant envelope glycoprotein on immune cell functions in vitro. Cell Immunol 1987;10:140-7.
16. Mann DL, Lasane F, Popovic M, et al. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol 1987;138:2640-4.
17. + cell function by the HIV envelope protein, gp120. J Immunol 1988;141:3715-7.
18. Lang W, Anderson RE, Perkins H, et al. Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome: the San Francisco men's health study. JAMA 1987;257:326-30.
19. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991;266:1664-7.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-5.
21. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. 1984. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-2.
22. Cremer NE, Gossen CK, Shell GR, Pereira L. Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. J Clin Microbiol 1985;21:517-21.
23. Cremer NE, Schmidt NJ, Jensen F, Hoffman M, Oshiro LS, Lennette EH. Complement-fixing antibody in human sera reactive with viral and soluble antigens of cytomegalovirus. J Clin Microbiol 1975;1:262-7.
24. Haigwood NL, Nara PL, Brooks E, et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992;66:172-82.
25. Haigwood NL, Shuster JR, Moore GK, et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses 1990;6:855-69.
26. Grenier K, Bach BA, Campbell D, Ullery S, Borowitz MJ. Discordant expression of T-cell activation markers (HLA-DR, CD38, CD25, CD69) as indicators of cellular immune response to HIV infection. FACS Monochronicle (Becton Dickinson - San Jose, CA) 1990;fall/winter:7-8.
27. + T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994;95:436-441.
28. Kornfield H, Cruikshank WW, Pyle SW, Berman JS, Center DM. Lymphocyte activation by HIV-1 envelope glycoprotein. Nature 1988;335:445-8.
29. Dell'Anna L, Carbonari M, Cibati M, Aiuti F, Fiorilli M. Insoluble gp120/anti-gp120 antibody complexes enhance T-cell activation, AIDS 1993;7:739-40.
30. Montagnier L, Blanchard A. Mycoplasma as cofactors in infection due to the human immunodeficiency virus. Clin Infect Dis 1993;17(suppl 1):S309-15.
31. Krowka JF, Sarin S, Namikawa R, McCune JM, Kaneshima H. Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol 1991;146:3751-6.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Krowka JF, Stiles DP, Jain S, et al. Lymphocyte proliferative responses to human immunodeficiency virus (HIV) antigens in vitro. J Clin Invest 1989;83:1198-203.
34. Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 1995;20:127-33.
35. Mittler RS, Hoffmann MK. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Science 1989;245:1380-2.
36. Klouse KA, Cosentino LM, Weih KA, et al. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991;147:2892-901.
37. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993;150:4601-9.
38. Kaufmann R, Laroche D, Buchner K, et al. The HIV-1 surface protein gp120 has no effect on transmembrane signal transduction in T cells. J AIDS 1992;15:760-70.
39. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988;73:165-7.
40. Sheppard HW, Ascher MS. The relationship between AIDS and immunological tolerance. J AIDS 1992;5:143-7.
41. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991;12:102-5.
42. Schneider J, Kaaden O, Copeland TD, Oroszlan S, Hunsmann G. Shedding and interspecies type sero-reactivity of the envelope glycopeptide gp120 of the human immunodeficiency virus. J Gen Virol 1986;67:2533-8.
43. Pyle SW, Bess JW, Robey WG, Fischinger PJ, Gilden RV, Arthur LO. Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells. AIDS Res Hum Retroviruses 1987;3:387-400.
44. Oh SK, Cruikshank WW, Raina J, et al. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J AIDS 1992;5:251-6.
45. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.